Upcoming Live from the Lab: EV Imaging Training register now>
European Business Magazine Features ONI as a Rising Disruptor in Life Sciences
Author: Nick Rushton
FOR IMMEDIATE RELEASE
European Business Magazine Features ONI as a Rising Disruptor in Life Sciences
SAN DIEGO, July 17, 2024 –
In a recent feature, European Business Magazine spotlighted ONI as a rising disruptor in the life sciences industry. Dr. Paul Scagnetti, CEO of ONI, shared his insights on the transformative potential of ONI’s super-resolution technology, its role in advancing personalized medicine, and the company’s vision for the future.
Our super-resolution technology is transforming the way scientists observe molecular interactions. Unlike traditional microscopes, our Nanoimager platform allows researchers to see individual molecules. This groundbreaking capability is crucial for personalized medicine and pharmacogenomics, enabling more precise drug discovery and targeted therapies.
Paul Scagnetti, CEO of ONI, explained, “We enable therapeutic discovery by helping people see through previous blind spots. Traditional microscopes can’t observe individual molecules, but our technology provides that detailed observation, allowing researchers to watch the entire journey of a therapeutic molecule.”
By making super-resolution microscopy more accessible, ONI is accelerating advancements in therapeutic discovery and diagnostics. Our integration of AI and machine learning further enhances this process, allowing for detailed analysis of molecular interactions and the creation of dynamic molecular movies. “Machine learning helps synthesize information, pulling out crucial details for researchers,” said Scagnetti. “Generative AI will enable us to create realistic molecular movies, allowing scientists to visualize interactions at the molecular level.”
Our global collaborations with top academic institutions and biopharma companies drive innovation and scientific progress. “We work with leading academics and pharma companies, each with unique needs,” Scagnetti shared. “This collaboration fuels innovation and accelerates scientific discoveries.”
At ONI, we’re dedicated to providing unprecedented insights into molecular interactions, revolutionizing drug design and manufacturing, and supporting researchers in achieving their scientific goals. Stay tuned for more updates as we continue to push the boundaries of what’s possible in life sciences!
Read the interview feature here or in the latest issue of European Business Magazine.
For media inquiries, please contact:
Jason Jell, PhD
Vice President of Marketing
jason@oni.bio
1.716.393.1163
FOR IMMEDIATE RELEASE
European Business Magazine Features ONI as a Rising Disruptor in Life Sciences
SAN DIEGO, July 17, 2024 –
In a recent feature, European Business Magazine spotlighted ONI as a rising disruptor in the life sciences industry. Dr. Paul Scagnetti, CEO of ONI, shared his insights on the transformative potential of ONI’s super-resolution technology, its role in advancing personalized medicine, and the company’s vision for the future.
Our super-resolution technology is transforming the way scientists observe molecular interactions. Unlike traditional microscopes, our Nanoimager platform allows researchers to see individual molecules. This groundbreaking capability is crucial for personalized medicine and pharmacogenomics, enabling more precise drug discovery and targeted therapies.
Paul Scagnetti, CEO of ONI, explained, “We enable therapeutic discovery by helping people see through previous blind spots. Traditional microscopes can’t observe individual molecules, but our technology provides that detailed observation, allowing researchers to watch the entire journey of a therapeutic molecule.”
Paul Scagnetti, CEO of ONI, explained, “We enable therapeutic discovery by helping people see through previous blind spots. Traditional microscopes can’t observe individual molecules, but our technology provides that detailed observation, allowing researchers to watch the entire journey of a therapeutic molecule.”
By making super-resolution microscopy more accessible, ONI is accelerating advancements in therapeutic discovery and diagnostics. Our integration of AI and machine learning further enhances this process, allowing for detailed analysis of molecular interactions and the creation of dynamic molecular movies. “Machine learning helps synthesize information, pulling out crucial details for researchers,” said Scagnetti. “Generative AI will enable us to create realistic molecular movies, allowing scientists to visualize interactions at the molecular level.”
Our global collaborations with top academic institutions and biopharma companies drive innovation and scientific progress. “We work with leading academics and pharma companies, each with unique needs,” Scagnetti shared. “This collaboration fuels innovation and accelerates scientific discoveries.”
At ONI, we’re dedicated to providing unprecedented insights into molecular interactions, revolutionizing drug design and manufacturing, and supporting researchers in achieving their scientific goals. Stay tuned for more updates as we continue to push the boundaries of what’s possible in life sciences!
Read the interview feature here or in the latest issue of European Business Magazine.
For media inquiries, please contact:
Jason Jell, PhD
Vice President of Marketing
jason@oni.bio
1.716.393.1163